Insta
IIT Madras Researchers' Study Could Pave The Way For Development Of Effective Drugs To Treat HIV-AIDS
IANS
Feb 18, 2021, 02:02 PM | Updated 02:02 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Indian Institute of Technology (IIT) Madras researchers are working on a new idea that may help develop effective drugs for treating HIV/AIDS.
Using molecular dynamics simulations, the research team have shown that introducing electrostatic interaction sites on potential drug molecules can enhance the efficacy of the antiviral drug against the HIV virus.
According to the researchers, the pressing need for better drugs to combat drug-resistant HIV strains led the team to delve into molecular structure of protease to identify weak sites that can offer a handle for better inhibitor development.
By using state-of-art computational techniques the team has uncovered vital data that can be used for design of more efficacious drugs, according to a paper published in the peer-review Journal of the American Chemical Society - Biochemistry.
"Current inhibitors that target HIVPR make use of the weak forces of attraction called 'van der Waal's forces' to attach themselves to the protease molecule. Given that these forces are weak, the efficacy of the drug is variable and the virus will soon become resistant to them," Sanjib Senapati, Department of Biotechnology, IIT Madras, said in a statement.
The Molecular Dynamics (MD) simulation studies conducted by the team have showed the presence of a strong and asymmetrical electric charge in the active site of the HIVPR.
If a drug molecule can be designed with a complementary charge, so that it can bind tightly with this active site through electrostatic attraction, it can permanently deactivate/inhibit the enzyme, the team said.
The team propose that drug design strategies should embrace both electrostatics and van der Waals interactions to complement the HIVPR active site architecture. Further, the team believes that such compounds will be effective against both wild type and resistant HIV variants.
This is a paradigm-shifting idea and will offer a whole new approach to the development of drugs for HIV-AIDS, the team said.
(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.